Nuveen
RGNX icon

Nuveen’s Regenxbio RGNX Stock Holding History

Nuveen’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.87M Buy
740,026
+158,010
+27% +$1.31M ﹤0.01% 1767
2026
Q1 		$4.88M Sell
582,016
-76,494
-12% -$804K ﹤0.01% 1895
2025
Q4 		$9.48M Buy
658,510
+106,363
+19% +$1.33M ﹤0.01% 1587
2025
Q3 		$5.33M Buy
552,147
+131,898
+31% +$1.17M ﹤0.01% 1878
2025
Q2 		$3.45M Buy
420,249
+295,549
+237% +$2.47M ﹤0.01% 2060
2025
Q1 		$892K Buy
124,700
+12,384
+11% +$92.1K ﹤0.01% 2686
2024
Q4 		$868K Hold
112,316
– – ﹤0.01% 2768
2024
Q3 		$1.18M Hold
112,316
– – ﹤0.01% 2682
2024
Q2 		$1.31M Buy
112,316
+6,548
+6% +$102K ﹤0.01% 2590
2024
Q1 		$2.23M Hold
105,768
– – ﹤0.01% 2351
2023
Q4 		$1.9M Buy
105,768
+3,591
+4% +$63.3K ﹤0.01% 2434
2023
Q3 		$1.68M Sell
102,177
-1,364
-1% -$24.7K ﹤0.01% 2372
2023
Q2 		$2.07M Hold
103,541
– – ﹤0.01% 2333
2023
Q1 		$1.96M Sell
103,541
-14,186
-12% -$314K ﹤0.01% 2339
2022
Q4 		$2.67M Sell
117,727
-17,640
-13% -$399K ﹤0.01% 2251
2022
Q3 		$3.58M Sell
135,367
-3,988
-3% -$118K ﹤0.01% 2089
2022
Q2 		$3.44M Buy
139,355
+12,889
+10% +$322K ﹤0.01% 2164
2022
Q1 		$3.67M Sell
126,466
-417
-0.3% -$11.6K ﹤0.01% 2224
2021
Q4 		$3.97M Sell
126,883
-10,616
-8% -$361K ﹤0.01% 2247
2021
Q3 		$6.19M Sell
137,499
-11,840
-8% -$426K ﹤0.01% 2095
2021
Q2 		$5.8M Sell
149,339
-16,128
-10% -$577K ﹤0.01% 2175
2021
Q1 		$5.64M Buy
165,467
+36,370
+28% +$1.55M ﹤0.01% 2115
2020
Q4 		$5.86M Sell
129,097
-2,502
-2% -$87.4K ﹤0.01% 1989
2020
Q3 		$3.62M Sell
131,599
-12,426
-9% -$405K ﹤0.01% 2093
2020
Q2 		$5.3M Buy
144,025
+4,390
+3% +$164K ﹤0.01% 1862
2020
Q1 		$4.52M Buy
139,635
+1,445
+1% +$60.2K ﹤0.01% 1766
2019
Q4 		$5.66M Sell
138,190
-42,929
-24% -$1.7M ﹤0.01% 1918
2019
Q3 		$6.45M Sell
181,119
-17,557
-9% -$711K ﹤0.01% 1819
2019
Q2 		$10.2M Buy
+198,676
New +$9.92M ﹤0.01% 1600

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Nuveen's RGNX Position: Q2 2026 in Review

Nuveen increased its Regenxbio (RGNX) stake by 27% in Q2 2026, buying an estimated $1.31M and bringing the position to 740,026 shares worth $8.87M. The position accounts for ﹤0.01% of the portfolio, ranked #1767.

Nuveen first reported a position in RGNX in Q2 2019 and has held it in 29 quarters since. The position peaked at $10.2M in Q2 2019. 164 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

  • Nuveen held 740,026 shares of Regenxbio worth $8.87M as of Q2 2026.
  • Nuveen bought 158,010 Regenxbio shares in Q2 2026, an estimated $1.31M.
  • Regenxbio made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1767 holding.
  • Nuveen first reported a position in Regenxbio in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Regenxbio position peaked at $10.2M in Q2 2019.
  • 164 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.